Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.
Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?
Experts in dialogue Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and prof. Kastelein talk about this topic and exchange their views on LDL-c lowering.
The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.
This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.
Large-scale observational data from the SWEDEHEART registry showed that in patients in clinical practice early and aggressive LDL-c lowering after MI was associated with reduced risk of major CV outcomes and mortality.
In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age.
Although relative risk for MI per 1 mmol/L higher LDL-c is similar across age groups, absolute risk for MI and ASCVD per LDL categories is much higher in individuals 80-100 years compared to those <70 years.
An observational study showed that the absolute risk of myopathy is low in patients taking simvastatin. A myopathy risk score showed no association with other muscle symptoms in these patients.
AHA 2020 Prof. Francis presents and interprets the findings of the SAMSON trial, in which symptom burden during statin, placebo and tablet-free periods was examined in patients who previously discontinued statins.
AHA 2020 The SAMSON trial showed that 90% of symptom burden in patients who previously discontinued statins is elicited by placebo tablets.
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.